Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

8.0K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
1.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

11.0K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
11.0K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

8.6K
Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Specificity in the management of gynecological cancers in French overseas departments].

Bulletin du cancer·2026
Same author

YAU-RCC Insights from ASCO GU 2026: emerging advances in renal cell carcinoma management.

Minerva urology and nephrology·2026
Same author

What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group.

World journal of urology·2026
Same author

Re: Circulating Kidney Injury Molecule-1 (KIM-1) and Association with Outcome to Adjuvant Immunotherapy in Renal Cell Carcinoma.

European urology·2026
Same author

Adenoid cystic carcinoma of the breast: a case series of 26 patients.

Breast cancer research and treatment·2026
Same author

Future approaches to immune-based biomarkers.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Related Experiment Video

Updated: Apr 12, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

8.4K

[FGF/FGFR signalling: Implication in oncogenesis and perspectives].

Ronan Flippot1, Moumini Kone2, Nicolas Magné3

  • 1Gustave-Roussy, département d'innovations thérapeutiques essais précoces, 94800 Villejuif-Grand Paris, France.

Bulletin Du Cancer
|May 20, 2015
PubMed
Summary

Fibroblast growth factor (FGF)/FGF receptor (FGFR) pathway deregulation drives cancer progression. Targeted therapies show promise, but patient screening for FGFR alterations is crucial for effective treatment.

Keywords:
AmplificationFGF receptorMelanomaMolecular targeted therapyMutationMélanomeThérapie moléculaire ciblée

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.9K
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

7.3K

Related Experiment Videos

Last Updated: Apr 12, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

8.4K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.9K
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

7.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Signal Transduction

Context:

  • Fibroblast growth factor (FGF) and FGF receptor (FGFR) signaling pathway dysregulation is implicated in numerous cancers.
  • This pathway's aberrant activation promotes key oncogenic mechanisms like proliferation, migration, and angiogenesis.
  • Understanding downstream signaling is vital for elucidating its oncogenic potential.

Purpose:

  • To detail the oncogenic mechanisms driven by FGF/FGFR signaling.
  • To explore the implications of FGF/FGFR pathway deregulation across various cancer types.
  • To highlight the role of FGF/FGFR signaling in melanoma, where it's a near-ubiquitous driver event.

Summary:

  • Deregulation of the FGF/FGFR pathway fuels cancer development by promoting proliferation, epithelial-mesenchymal transition, migration, and angiogenesis.
  • In melanoma, FGF/FGFR pathway alterations are driver events in approximately 90% of cases.
  • The FGF/FGFR pathway is a therapeutic target, with ongoing development of selective and multi-targeted agents.

Impact:

  • Targeted therapies for FGF/FGFR alterations are under development, showing promise in selected patient populations.
  • Recent clinical trials indicate that efficacy is linked to the presence of specific FGF/FGFR pathway alterations.
  • Patient stratification through careful screening is essential for evaluating the success of novel molecular therapies targeting this pathway.